Patent application

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

Friday, March 27, 2020 - 12:30am

IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.

Key Points: 
  • IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.
  • A public copy of the patent is available on the USPTO website.
  • A patent for an invention is the grant of a property right to the inventor, issued by the USPTO.
  • The company is based in Maryland, U.S.A. Our website: www.igcinc.us .Twitter @IGCIR
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005803/en/

Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders

Thursday, March 19, 2020 - 1:00pm

"With this Patent, we are honored that so many jurisdictions have recognized our IP estate as novel and proprietary," said Dean Petkanas, CEO of Kannalife.

Key Points: 
  • "With this Patent, we are honored that so many jurisdictions have recognized our IP estate as novel and proprietary," said Dean Petkanas, CEO of Kannalife.
  • Additionally, Kannalife has national phase patent applications based on the PCT Patent application pending in Canada, Brazil and India.
  • Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com .
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Thursday, March 19, 2020 - 1:00pm

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP molecule.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP molecule.
  • Based on these results the company has filed for patent protection with the United States Patent and Trademark Office (USPTO) for the application of DED.
  • Dry Eye Disease is one of the most common ocular problems with an estimated prevalence of almost 5-million people over the age of fifty in the United States alone.
  • Current therapies for dry eye are palliative with a focus on the replacement of tears to reduce symptoms.

JTI Ranks Among Top 100 for European Patent Applications

Thursday, March 19, 2020 - 8:00am

GENEVA, March 19, 2020 /PRNewswire/ -- JTI was one of the top 100 applicants at the European Patent Office (EPO), according to the EPO's Patent Index 2019.

Key Points: 
  • GENEVA, March 19, 2020 /PRNewswire/ -- JTI was one of the top 100 applicants at the European Patent Office (EPO), according to the EPO's Patent Index 2019.
  • Globally, the JT Group has a portfolio of 4200 granted patents and 2800 pending patent applications, with 355 priority applications filed by the Group in 2019, covering the development of its diverse product families.
  • JTI is also a major player in the international vaping market with its brand, Logic and tobacco vapor brand, Ploom.
  • Headquartered in Geneva, Switzerland, JTI employs approximately 45,000 people and was awarded Global Top Employer for the sixth consecutive year.

2020 Microfluidics Start-up Identification Report - 50+ Start-ups Identified & Mapped

Friday, March 13, 2020 - 4:15pm

DUBLIN, March 13, 2020 /PRNewswire/ -- The "Microfluidics Start-up Identification" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 13, 2020 /PRNewswire/ -- The "Microfluidics Start-up Identification" report has been added to ResearchAndMarkets.com's offering.
  • In this report, the publisher has therefore investigated Microfluidics-related patents in order to identify startups through their patent filings.
  • This study reveals that Oncology is by far the market explored the most by startups working in the field of Microfluidics.
  • For each startup identified, the report provides a complete description of its activity and products/prototypes.

SJW Group Announces Postponement of San Jose Water’s Cost of Capital Filing

Thursday, March 12, 2020 - 10:00pm

On January 22, 2020 the Joint Parties filed a request for a one-year postponement of their COC filings otherwise scheduled to be filed on May 1, 2020.

Key Points: 
  • On January 22, 2020 the Joint Parties filed a request for a one-year postponement of their COC filings otherwise scheduled to be filed on May 1, 2020.
  • Pursuant to the CPUCs rate case plan, the Joint Parties are required to file their COC applications on a triennial basis.
  • Postponing the filing for one year alleviates administrative processing costs for both the Joint Parties and CPUC staff.
  • SJW Group remains focused on investing in its operations, remaining actively engaged in its local communities and delivering continued sustainable value to its shareholders.

AI Drives Patent Applications from U.S. Companies at the European Patent Office to New Record High

Thursday, March 12, 2020 - 12:00pm

MUNICH, Germany, March 12, 2020 /PRNewswire-PRWeb/ -- The European Patent Office (EPO) today announced that U.S. companies and inventors filed over 46,200 European patent applications in 2019, 5.5% more than in the previous year, according to its Patent Index 2019 (Graph: Growth of patent applications at the EPO from the U.S. ).

Key Points: 
  • MUNICH, Germany, March 12, 2020 /PRNewswire-PRWeb/ -- The European Patent Office (EPO) today announced that U.S. companies and inventors filed over 46,200 European patent applications in 2019, 5.5% more than in the previous year, according to its Patent Index 2019 (Graph: Growth of patent applications at the EPO from the U.S. ).
  • With a share of 25% of all patent applications, the U.S. remained the most active country of origin for patent applications filed with the EPO (Graph: Origin of applications ).
  • Overall, the European Patent Office received 181,000 patent applications in 2019, an increase of 4% compared to 2018 (Graph: Growth of European patent applications ).
  • With nearly 7,000 staff, the European Patent Office (EPO) is one of the largest public service institutions in Europe.

Worksport Achieves First Canadian Patent Claim Allowance

Wednesday, March 4, 2020 - 1:00pm

Worksport Ltd has be awarded patent claims in Canada, marking the companies first ever Canadian patent asset.

Key Points: 
  • Worksport Ltd has be awarded patent claims in Canada, marking the companies first ever Canadian patent asset.
  • This marks Worksports first Canadian patent asset and another milestone for the company and its shareholders alike.
  • Worksport is now enviably positioned in both the U.S and Canadian markets to begin releasing its unique truck bed cover systems said Steven Rossi, CEO of Worksport.
  • This follows the USPTO (U.S Patent and Trademark Office) allowing all claims for the same patent application in November, 2019.

Salarius Announces Allowance of New European Patent Covering Seclidemstat

Wednesday, March 4, 2020 - 1:00pm

The European Patent Office (EPO) has recently issued a notice of allowance for Patent EP274430 exclusively licensed to Salarius from the University of Utah Research Foundation indicating that the agency is satisfied that the patent application meets all EPO requirements.

Key Points: 
  • The European Patent Office (EPO) has recently issued a notice of allowance for Patent EP274430 exclusively licensed to Salarius from the University of Utah Research Foundation indicating that the agency is satisfied that the patent application meets all EPO requirements.
  • In all, Salarius holds 22 issued patents in the U.S. and abroad.
  • Meanwhile, Salarius has 11 patent applications pending approval in Europe, Brazil, Canada, Israel, India, Korea, Mexico, Singapore and China.
  • All 22 issued patents and the 11 pending applications are directed to Seclidemstat or structurally similar compounds.

BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer

Thursday, February 27, 2020 - 12:43pm

The PD-1 antagonist can be any agent that prevents and/or inhibits the biological function and/or expression of PD-1, such as pembrolizumab (KEYTRUDA).

Key Points: 
  • The PD-1 antagonist can be any agent that prevents and/or inhibits the biological function and/or expression of PD-1, such as pembrolizumab (KEYTRUDA).
  • This patent, whenmedi issued, will be valid until July 2036 with a possibility of up to five years patent term extension.
  • Additional corresponding patent applications are pending in Europe, Japan, China, Canada, Australia, India, Korea, Mexico, Brazil and Israel.
  • The study is being conducted by BioLineRx under a collaboration agreement signed in 2016 between BioLineRx and MSD, through a subsidiary.